Anavex assumed with a Buy at Maxim. Maxim analyst Caroline Palomeque assumed Anavex with a Buy rating and raised her price target to $7 from the prior $5. The analyst says she is factoring in additional revenue from further indications in Rett syndrome and Parkinson's disease on top of the company's Alzheimer's disease stream. with potential catalysts from the emerging data on the expanded 2-73 programs coming out in the second half of the year.

Anavex Life Sciences announced that the company is planning to initiate a Phase 2 clinical trial of lead candidate ANAVEX2-73 in Parkinson's Disease Dementia, or PDD. The company is moving forward with a Phase 2 trial with ANAVEX2-73 in PDD, which will study the effect of the compound on both the cognitive and motor impairment of Parkinson's disease. The double-blind, randomized, placebo-controlled Phase 2 PDD study has been submitted to regulatory authorities in Europe, and pending approval, the company plans to initiate this clinical trial H2 2018. Additional protocol details will be shared at that point. The earlier studies of ANAVEX2-73 in a disease modifying model of Parkinson's disease were funded by The Michael J. Fox Foundation for Parkinson's Research.

Anavex initiated with a Buy at Roth Capital. Roth Capital analyst Robert LeBoyer started Anavex with a Buy rating and $6 price target as the company plans to advance ANAVEX 2-73 to Phase 2b/3 clinical trials for Alzheimer's disease, a Phase 2 for Rett syndrome, and to file an IND to begin a Phase 2 study for Parkinson's disease.

Conference Call to discuss earnings for the Q1, as well as provide a clinical update on the Company's most advanced clinical programs for ANAVEX(R)2-73, will be held on February 7 at 4:30 pm. Webcast Link

Conference Call to discuss earnings for the Q1, as well as provide a clinical update on the Company's most advanced clinical programs for ANAVEX(R)2-73, will be held on February 7 at 4:30 pm. Webcast Link

14th Annual Institutional Investor Conference is being held in Fort Lauderdale, FL on January 29-30 with webcasted company presentations to begin on January 29 at 9 am; not all company presentations may be webcasted. Webcast Link

14th Annual Institutional Investor Conference is being held in Fort Lauderdale, FL on January 29-30 with webcasted company presentations to begin on January 29 at 9 am; not all company presentations may be webcasted. Webcast Link

Anavex Life Sciences reports that the peer-reviewed scientific journal The Journal of Clinical Hypertension has published a post-hoc analysis of blood pressure data collected during the Phase 2a study in mild-to-moderate Alzheimer's disease patients demonstrating that ANAVEX2-73 seems to normalize systolic blood pressure, or SBP, in a patient population with risk for hypertension. Statistical analyses including paired t-testing and multivariable linear mixed effects modeling indicate a normalization of SBP from the first reading of 143.3 mmHg to the subsequent readings after ANAVEX2-73 administration of 132.5 mmHg at day 25 and of 135.3 mmHg at day 36, respectively. High blood pressure, or hypertension, occurs when either systolic or diastolic pressure remains elevated over time. High blood pressure is dangerous because it makes the heart work too hard and its extra force can damage arteries. Uncontrolled high blood pressure can lead to heart disease, kidney damage or stroke. New evidence also links high blood pressure to increased risk of cognitive decline and dementia.

Management discusses financial results for fiscal year ended September 30, 2017, as well as provides an update on ANAVEX 2-73 for treatment of Rett syndrome (RTT) on a conference call to be held on December 11 at 4:30 pm. Webcast Link

Management discusses financial results for fiscal year ended September 30, 2017, as well as provides an update on ANAVEX 2-73 for treatment of Rett syndrome (RTT) on a conference call to be held on December 11 at 4:30 pm. Webcast Link